Tarsus Pharmaceuticals, Inc. TARS
We take great care to ensure that the data presented and summarized in this overview for Tarsus Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TARS
View all-
Rtw Investments, LP New York, NY3.41MShares$118 Million1.55% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$113 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.44MShares$84 Million2.68% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$77.8 Million7.48% of portfolio
-
Cowen And Company, LLC2.2MShares$75.8 Million1.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$68.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.88MShares$65 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.59MShares$54.8 Million2.54% of portfolio
-
Jennison Associates LLC1.48MShares$51.1 Million0.03% of portfolio
-
Perceptive Advisors LLC New York, NY1.3MShares$44.7 Million1.02% of portfolio
Latest Institutional Activity in TARS
Top Purchases
Top Sells
About TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Insider Transactions at TARS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2024
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,333
+18.14%
|
-
|
|
Aug 12
2024
|
William J Phd Link |
SELL
Open market or private sale
|
Indirect |
35,000
-92.83%
|
$910,000
$26.27 P/Share
|
|
Aug 12
2024
|
William J Phd Link |
BUY
Other acquisition or disposition
|
Direct |
27,116
+13.96%
|
-
|
|
Aug 12
2024
|
William J Phd Link |
BUY
Other acquisition or disposition
|
Indirect |
10,446
+50.0%
|
-
|
|
Aug 12
2024
|
William J Phd Link |
SELL
Other acquisition or disposition
|
Indirect |
74,892
-68.15%
|
-
|
|
Jun 24
2024
|
William J Phd Link |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+2.34%
|
-
|
|
Jun 24
2024
|
Andrew D. Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+34.54%
|
-
|
|
Jun 24
2024
|
Rosemary A Crane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+38.51%
|
-
|
|
Jun 24
2024
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+24.45%
|
-
|
|
Jun 24
2024
|
Bhaskar Chaudhuri Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+38.51%
|
-
|
|
Jun 24
2024
|
Scott W Morrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+41.7%
|
-
|
|
Jun 24
2024
|
Elizabeth Yeu Lin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,350
+38.51%
|
-
|
|
Jun 18
2024
|
Jeffrey S Farrow Officer |
SELL
Open market or private sale
|
Direct |
10,445
-36.55%
|
$282,015
$27.47 P/Share
|
|
Jun 17
2024
|
Jeffrey S Farrow Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,881
+49.38%
|
-
|
|
Mar 18
2024
|
Bobak R. Azamian President/CEO and Board Chair |
SELL
Open market or private sale
|
Direct |
10,415
-28.25%
|
$312,450
$30.6 P/Share
|
|
Mar 18
2024
|
Bryan Wahl General Counsel |
SELL
Open market or private sale
|
Direct |
4,436
-9.77%
|
$133,080
$30.6 P/Share
|
|
Mar 18
2024
|
Aziz Mottiwala Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,766
-8.1%
|
$142,980
$30.6 P/Share
|
|
Mar 18
2024
|
Seshadri Neervannan Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,879
-7.01%
|
$146,370
$30.6 P/Share
|
|
Mar 18
2024
|
Dianne C. Whitfield Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
4,314
-11.21%
|
$129,420
$30.6 P/Share
|
|
Mar 15
2024
|
Bobak R. Azamian President/CEO and Board Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
28,274
+43.4%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 184K shares |
|---|---|
| Other acquisition or disposition | 37.6K shares |
| Open market or private purchase | 1K shares |
| Open market or private sale | 167K shares |
|---|---|
| Other acquisition or disposition | 74.9K shares |